SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-22-013941 to MESOBLAST LTD (MESO, MEOBF) (CIK 0001345099) (MESO)

MESOBLAST LTD (MESO, MEOBF) (CIK 0001345099)
Date: Dec. 28, 2022 · CIK: 0001345099 · Accession: 0000000000-22-013941

AI Filing Summary & Sentiment

File numbers found in text: 333-268890

Date
December 28, 2022
Author
Not clearly detected
Form
UPLOAD
Company
MESOBLAST LTD (MESO, MEOBF) (CIK 0001345099)

Letter

United States securities and exchange commission logo December 28, 2022 Silviu Itescu Chief Executive Officer MESOBLAST LTD Level 38, 55 Collins Street Melbourne, VIC 3000, Australia Re:MESOBLAST LTD Registration Statement on Form F-3 Filed December 20, 2022 File No. 333-268890 Dear Silviu Itescu: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text
United States securities and exchange commission logo
December 28, 2022
Silviu Itescu
Chief Executive Officer
MESOBLAST LTD
Level 38, 55 Collins Street
Melbourne, VIC 3000, Australia
Re:MESOBLAST LTD
Registration Statement on Form F-3
Filed December 20, 2022
File No. 333-268890
Dear Silviu Itescu:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences